Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218705 · ClinicalTrials.gov registry record
A Study Of MCG In Cardiac Amyloidosis
A clinical trial of Amyloidosis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT07218705 is a study of Amyloidosis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 500 participants, below the 1,111-participant average among 28 other Amyloidosis trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07218705, a study of Amyloidosis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.
Conditions Studied
Interventions
- DEVICE SandboxAQ CardiAQ Magnetocardiography
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2027-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218705
The ClinicalTrials.gov registry entry for NCT07218705 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,111-participant average among 28 other Amyloidosis trials with a reported enrollment target (55% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which SandboxAQ CardiAQ Magnetocardiography is the first listed.
NCT07218705 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT07218705 about?
NCT07218705 is a clinical study titled "A Study Of MCG In Cardiac Amyloidosis". The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.
What is the current status of trial NCT07218705?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-12-03. Estimated completion is 2027-11.
What conditions does trial NCT07218705 study?
This clinical trial studies the following conditions: Amyloidosis.
What interventions are being tested in trial NCT07218705?
The interventions under investigation include: SandboxAQ CardiAQ Magnetocardiography (DEVICE).
Who is sponsoring clinical trial NCT07218705?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218705 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RECRUITING
-
A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
RECRUITING
-
Dietary Reporting in the Amyloidoses
RECRUITING · NA
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.